Product Images Opdualag

This is a description of a medication called Opdivo, which is available in a 20mL single-dose vial containing 240mg of nivolumab and 80mg of relatimab. Each mL of the vial has 12mg of ivolmab, mg of elatinab, and 1.1mg of istdie. Other ingredients include Listine hydrochioride monobyrate, pentetic acd, pobsorbat 80, sucross. It is for intravenous infusion only and is recommended to be administered through an intravenous finecontaining. The vial must be stored at 20-25°C (36°F to 46%) and protected from light until use. It is important to note that this information is not the standard of potency and that the dosage should be determined by prescription only.*

This is a graph representing the Probability of Progression Free Survival of two groups - OPDUALAG and Nivolumab. The graph shows the percentage of patients who were able to survive without any progression of their condition after a certain number of months. The x-axis represents time in months, while the y-axis represents the probability of survival. The group treated with Nivolumab had a higher probability of progression-free survival compared to the group treated with OPDUALAG. The number of subjects at risk in the two groups is also shown at different time points.*